XML 68 R55.htm IDEA: XBRL DOCUMENT v3.21.2
Geneos Therapeutics, Inc. - Narrative (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 7 Months Ended
Jun. 01, 2020
Nov. 30, 2020
Feb. 28, 2019
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Dec. 31, 2020
Feb. 28, 2021
Mar. 31, 2020
Jan. 31, 2020
Noncontrolling Interest [Line Items]                        
Gain on deconsolidation of investment       $ 0   $ 4,121,075 $ 0 $ 4,121,075        
Share of net loss in Geneos       0   $ 901,757 434,387 $ 901,757        
Investment in equity method investments       $ 0     $ 0   $ 434,387      
Series A One Preferred Stock                        
Noncontrolling Interest [Line Items]                        
Investment in equity method investments $ 1,399,999                      
Geneos Therapeutics, Inc.                        
Noncontrolling Interest [Line Items]                        
Noncontrolling interest, ownership percentage by parent   36.00% 61.00%             35.00% 52.00%  
Ownership percentage       47.00%   47.00% 47.00% 47.00%        
Geneos Therapeutics, Inc.                        
Noncontrolling Interest [Line Items]                        
Payments to acquire additional interest in subsidiaries   $ 1,400,000 $ 1,200,000                  
Stock purchase agreement, commitment of additional investment           $ 800,000   $ 800,000       $ 800,000
Gain on deconsolidation of investment 4,121,075                      
Deconsolidation gain, remeasurement of retained noncontrolling investment to fair value 2,400,000                      
Loss from equity method investment, recorded and allocated to investment         $ (1,500,000)       (4,600,000)      
Share of net loss in Geneos         434,387       4,584,610      
Investment in equity method investments 3,618,998     $ 0 0   $ 0          
Geneos Therapeutics, Inc. | Common stock                        
Noncontrolling Interest [Line Items]                        
Investment in equity method investments 819,000       0              
Geneos Therapeutics, Inc. | Preferred stock                        
Noncontrolling Interest [Line Items]                        
Share of net loss in Geneos                 4,200,000      
Investment in equity method investments $ 2,799,998       $ 0              
Geneos Therapeutics, Inc. | Series A One Preferred Stock                        
Noncontrolling Interest [Line Items]                        
Share of net loss in Geneos                 $ 819,000